Bring the power of CyTOF to COVID-19 research: Mass cytometry in infectious disease
04 May 2020

The COVID-19 public health crisis affects everyone in our global community. Crucial questions about how SARS-CoV-2 affects our immune system and how to monitor the response to newly developed therapeutic interventions must be answered, and quickly.

In this webinar, available at two separate sessions on May 4 and 5, Dr. Andrew Quong, Chief Science Officer at Fluidigm, will describe the important role that cytometry is playing in these efforts as well as how researchers are already using mass cytometry to monitor the immune response to a COVID-19 therapeutic approach. In addition, he will explain the Maxpar® Direct™ Immune Profiling System: a fast, reliable cytometric assay that includes an automated data analysis solution designed for use on CyTOF® systems.

Roberto Spada, Senior Market Development Manager, will share results of a multi-site study with the Maxpar® Direct™ Immune Profiling System that illustrates the inter-site and intra-site reproducibility of the assay. He will also present data showing that samples processed with the assay can be cryopreserved for up to four months without adverse impact on immune cell subset identification and enumeration.

For research use only. Not for use in diagnostic procedures.

Fluidigm Corporation